Episode Details
Back to Episodes
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
Published 3 years, 3 months ago
Description
Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literature remains relevant. We also discuss the latest news in the life sciences, including the abrupt resignation of the celebrity scientist who led Stanford University and the implications of tornado damage at a Pfizer plant.